Baidu
map

Lancet infect dis:当前在东南亚爆发的多重耐性性疟疾的起源

2018-02-02 MedSci MedSci原创

抗疟疾耐药性正在双氢青蒿素-哌喹用作一线治疗恶性疟原虫疟疾的东南亚地区迅速蔓延开来。2013年,柬埔寨西部首次发表了关于抗疟药耐药性的报告。Roberto Amato等人对该报告之前的6年里柬埔寨西部恶性疟原虫种群的遗传变化进行分析。研究人员对来自贯穿东南亚的11个地点的1492份恶性疟原虫样本(包括2007年-2013年间在柬埔寨西部收集的464份)的基因组序列数据进行分析。耐药性的不同流行病学

抗疟疾耐药性正在双氢青蒿素-哌喹用作一线治疗恶性疟原虫疟疾的东南亚地区迅速蔓延开来。2013年,柬埔寨西部首次发表了关于抗疟药耐药性的报告。Roberto Amato等人对该报告之前的6年里柬埔寨西部恶性疟原虫种群的遗传变化进行分析。

研究人员对来自贯穿东南亚的11个地点的1492份恶性疟原虫样本(包括2007年-2013年间在柬埔寨西部收集的464份)的基因组序列数据进行分析。耐药性的不同流行病学来源是通过对Kelch13青蒿素耐药位点和plasmepsin 2-3 哌喹耐药位点的单倍型分析进行鉴别。

研究人员发现了30多个独立的青蒿素耐药来源,其中,KEL1家系可解释91%(140/154)的对双氢青蒿素耐药的寄生虫。2008年,KEL1与PLA1相结合,PLA1是与哌喹耐药相关的主要家系。截止2013年,KEL1/PLA1共家系在柬埔寨西部的遗传频率已达63%,并且传播到了柬埔寨北部。

KEL1/PLA1共家系在双氢青蒿素-哌喹在柬埔寨西部成为一线抗疟疾药物的同一年出现,随后迅速蔓延,替代了其他青蒿素耐药性的疟原虫家系。这些发现对管理与当前在东南亚爆发的多重耐药性疟疾相关的全球健康风险具有重要意义。

原始出处:

Roberto Amato,et al.Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic study. The Lancet Infectious Dieases. February 01, 2018.https://doi.org/10.1016/S1473-3099(18)30068-9

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1829463, encodeId=f17b182946330, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Jun 22 14:39:00 CST 2018, time=2018-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012568, encodeId=9ceb201256897, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Feb 25 23:39:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286860, encodeId=31d6286860df, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sat Feb 10 21:23:35 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285141, encodeId=062328514140, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Feb 04 21:37:59 CST 2018, time=2018-02-04, status=1, ipAttribution=)]
    2018-06-22 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1829463, encodeId=f17b182946330, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Jun 22 14:39:00 CST 2018, time=2018-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012568, encodeId=9ceb201256897, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Feb 25 23:39:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286860, encodeId=31d6286860df, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sat Feb 10 21:23:35 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285141, encodeId=062328514140, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Feb 04 21:37:59 CST 2018, time=2018-02-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1829463, encodeId=f17b182946330, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Jun 22 14:39:00 CST 2018, time=2018-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012568, encodeId=9ceb201256897, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Feb 25 23:39:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286860, encodeId=31d6286860df, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sat Feb 10 21:23:35 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285141, encodeId=062328514140, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Feb 04 21:37:59 CST 2018, time=2018-02-04, status=1, ipAttribution=)]
    2018-02-10 天涯183

    非常好的文章.学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1829463, encodeId=f17b182946330, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Jun 22 14:39:00 CST 2018, time=2018-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012568, encodeId=9ceb201256897, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Feb 25 23:39:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=286860, encodeId=31d6286860df, content=非常好的文章.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7LIiaRZTzJ3SEfiauCzTMPW7YvPPYLNJBXG9oh6Al1icq2VQQkIHWxqXehcicTS62YKJVBhxeth3wggw/0, createdBy=7ce01621306, createdName=天涯183, createdTime=Sat Feb 10 21:23:35 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285141, encodeId=062328514140, content=学习了.谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Feb 04 21:37:59 CST 2018, time=2018-02-04, status=1, ipAttribution=)]
    2018-02-04 虈亣靌

    学习了.谢谢作者分享!

    0

相关资讯

Sci Tran Med: SAAP-148,一种新型抗耐药菌武器

自从抗生素发明以来,多重耐药菌(multidrug-resistant bacteria,MDRB)正在突破抗生素的最后一道防线,这使得科学家不得不从有毒青蛙,土壤中的细菌和其他野生动物中寻找新的抗生素化合物。科学家最近发现了一种特殊的微生物杀手,通过调整在人体中发现的一种天然存在的多肽(LL-37,一种短链氨基酸)的结构,设计出一种新的药物,可以消灭顽固的 MDRB。

三氯生可能有助于抗击耐药性疟疾

牙膏中的有效成分三氯生近日被发现可以用作抗疟疾药物,特别是耐药性疟疾。研究人员使用人工智能机器人“Eve”进行高通量筛选,发现三氯生(许多牙膏中的成分)可能有助于抗击耐药性疟疾。

N Engl J Med:儿童和青少年耐药性癫痫的治疗:手术vs药物

2017年发表在《N Engl J Med》上的一项单中心试验,对改善儿童和青少年耐药性癫痫的发作中的脑手术+合理的药物治疗和仅接受药物治疗进行了分析比较。

Clin Infect Dis:目前预防造血干细胞移植受体GNR相关菌血症耐药性的方法管用吗?

2017年发表在《Clin Infect Dis》的一项由以色列、意大利、荷兰、土耳其等国科学家进行的跨洲研究,考察了造血干细胞移植(HSCT)中革兰阴性杆菌(GNR)相关菌血症的抗菌药耐药性。

抗生素耐药性危害近在眼前

“你知道抗生素对细菌性感冒才有效,病毒性感冒无需使用抗生素吗?”

EUR J Cancer:致癌性miRNA及其在乳腺癌治疗中的重要性

小分子核糖核酸(microRNA,缩写为miRNA),又译为微核糖核酸,是真核生物中广泛存在的一种长约21到23个核苷酸的核糖核酸(RNA)分子,可调节其他基因的表达。miRNA来自一些从DNA转录而来,但无法进一步转译成蛋白质的RNA(属于非编码RNA)。miRNA通过与目标信使核糖核酸(mRNA)结合,进而抑制转录后的基因表达,在调控基因表达、细胞周期、生物体发育时序等方面起重要作用。

Baidu
map
Baidu
map
Baidu
map